- Serotonin-Norepinephrine Reuptake Inibitors (SNRI)
- Desvenlafaxine
- Venlafaxine
- Chronic Liver Disease (hepatic insufficiency or Cirrhosis)
- Serotonin Syndrome
- Glomerular Filtration Rate <30 ml/min
- Strong Serotonin and Norepinephrine reuptake inhibitor
- Also with minor Dopamine reuptake inhibitor properties
- Duloxetine Hydrochloride delayed release tablets (20g, 30 mg, 60 mg)
- Start: 20 mg orally twice daily or 30 mg orally daily
- Advance to 60 mg daily (or divided twice daily)
- Maximum: 120 mg/day
- Metabolized by CYP1A2 and CYP2D6
- Avoid with strong CYP1A2 or CYP2D6 Inhibitors
-
Monoamine Oxidase Inhibitors (MAO Inhibitor), including Linezolid
- Do not use Duloxetine concurrently or within 14 days of last dose of MAO Inhibitors
- Avoid with Methylene Blue, Thioridazine
- Unknown safety in Lactation
- Pregnancy Category: C
- Black box warning as for all Antidepressants for Suicidality in teens
- Nausea
- Xerostomia (Dry Mouth)
- Somnolence
- Constipation
- Decreased Appetite
- Hyperhidrosis
- Urinary Retention
- Hepatotoxicity
- (2023) Med Lett Drugs Ther 62(1592): 25-32
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 38-9
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- Jaouen and Lovecchio (2021) Crit Dec Emerg Med 31(12): 24